Massachusetts Institute of Technology

Paul J Soltys

Robert Samuel Langer

Claudy J Mullon

Levels of bilirubin in mammalian serum are controlled by administering to the mammalian intestinal tract a substance (a 'bilirubin deactivator') that converts unconjugated bilirubin into nontoxic, physiologically compatible products, thereby reducing reabsorption of unconjugated bilirubin in enterohepatic circulation. Useful bilirubin deactivators include those which specifically adsorb the bilirubin and are excreted, and 'bilirubin conversion enzymes', i.e., enzymes that operate on the unconjugated bilirubin substrate to yield products that are physiologically compatible in that they are not reabsorbed, or, if reabsorbed, they are nontoxic in the blood stream.

Growing community of inventors

Somerville, MA, United States of America

Paul J Soltys